219 related articles for article (PubMed ID: 10208456)
1. Expression of transforming growth factor beta1 and its receptors in normal human urothelium and human transitional cell carcinomas.
Izadifar V; de Boer WI; Muscatelli-Groux B; Maillé P; van der Kwast TH; Chopin DK
Hum Pathol; 1999 Apr; 30(4):372-7. PubMed ID: 10208456
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma.
Messing EM
Cancer Res; 1990 Apr; 50(8):2530-7. PubMed ID: 1690599
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas.
Diez de Medina SG; Chopin D; El Marjou A; Delouvée A; LaRochelle WJ; Hoznek A; Abbou C; Aaronson SA; Thiery JP; Radvanyi F
Oncogene; 1997 Jan; 14(3):323-30. PubMed ID: 9018118
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
Tokunaga H; Lee DH; Kim IY; Wheeler TM; Lerner SP
Clin Cancer Res; 1999 Sep; 5(9):2520-5. PubMed ID: 10499628
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis.
Logullo AF; Nonogaki S; Miguel RE; Kowalski LP; Nishimoto IN; Pasini FS; Federico MH; Brentani RR; Brentani MM
J Oral Pathol Med; 2003 Mar; 32(3):139-45. PubMed ID: 12581383
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
Sun W; Herrera GA
Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
[TBL] [Abstract][Full Text] [Related]
7. Quantification of transforming growth factor beta1 (TGFbeta1) mRNA expression in mouse preimplantation embryos and determination of TGFbeta receptor (type I and type II) expression in mouse embryos and reproductive tract.
Chow JF; Lee KF; Chan ST; Yeung WS
Mol Hum Reprod; 2001 Nov; 7(11):1047-56. PubMed ID: 11675471
[TBL] [Abstract][Full Text] [Related]
8. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
Le Frère-Belda MA; Cappellen D; Daher A; Gil-Diez-de-Medina S; Besse F; Abbou CC; Thiery JP; Zafrani ES; Chopin DK; Radvanyi F
Br J Cancer; 2001 Nov; 85(10):1515-21. PubMed ID: 11720438
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Kang Y; Mariano JM; Angdisen J; Moody TW; Diwan BA; Wakefield LM; Jakowlew SB
Mol Carcinog; 2000 Oct; 29(2):112-26. PubMed ID: 11074608
[TBL] [Abstract][Full Text] [Related]
11. Overactivity or blockade of transforming growth factor-β each generate a specific ureter malformation.
Lopes FM; Roberts NA; Zeef LA; Gardiner NJ; Woolf AS
J Pathol; 2019 Dec; 249(4):472-484. PubMed ID: 31400222
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratins in normal and malignant transitional epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines.
Moll R; Achtstätter T; Becht E; Balcarova-Ständer J; Ittensohn M; Franke WW
Am J Pathol; 1988 Jul; 132(1):123-44. PubMed ID: 2456018
[TBL] [Abstract][Full Text] [Related]
13. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
14. Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells.
De Boer WI; Houtsmuller AB; Izadifar V; Muscatelli-Groux B; Van der Kwast TH; Chopin DK
Int J Cancer; 1997 Apr; 71(2):284-91. PubMed ID: 9139855
[TBL] [Abstract][Full Text] [Related]
15. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
16. Variable Bcl-2 phenotype in benign and malignant lesions of urothelium.
Bilim VN; Tomita Y; Kawasaki T; Takeda M; Takahashi K
Cancer Lett; 1998 Jun; 128(1):87-92. PubMed ID: 9652797
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells.
Wang J; Han W; Zborowska E; Liang J; Wang X; Willson JK; Sun L; Brattain MG
J Biol Chem; 1996 Jul; 271(29):17366-71. PubMed ID: 8663343
[TBL] [Abstract][Full Text] [Related]
19. Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast.
Chakravarthy D; Green AR; Green VL; Kerin MJ; Speirs V
Int J Oncol; 1999 Jul; 15(1):187-94. PubMed ID: 10375614
[TBL] [Abstract][Full Text] [Related]
20. Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, TGFbeta3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer.
Nilsson E; Doraiswamy V; Parrott JA; Skinner MK
Mol Cell Endocrinol; 2001 Sep; 182(2):145-55. PubMed ID: 11514049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
